We have discussed the use of naftidrofuryl oxalate (Praxilene - Lipha) in peripheral vascular disease, senile dementia and acute cerebrovascular disease several times over the past 16 years. On each occasion we concluded that the evidence that naftidrofuryl gave clinical benefit was at best equivocal, and further trials were needed. We now review recent trials and other new information about the drug.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.